AstraZeneca says efzimfotase alfa meets primary endpoint in Phase 3 MULBERRY trial for pediatric hypophosphatasia

• AstraZeneca flagged late-breaking Phase 3 MULBERRY results, already presented at a pediatric bone health meeting in Montreal.
• Efzimfotase alfa improved bone health in treatment-naïve children with hypophosphatasia versus placebo, supporting clinically meaningful benefit.
• Safety and tolerability were described as favorable across the Phase 3 program, including children switching from Strensiq, with bone health maintained.
• Data reinforce a potential every-two-weeks, self-administered dosing profile, positioning efzimfotase alfa as a more convenient alternative to current therapy.
• Full Phase 3 HICKORY results in adolescents and adults are set for disclosure at a future medical meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AstraZeneca plc published the original content used to generate this news brief via Cision (Ref. ID: 202606290249BITN____UKPR__SV_20260629-BIT-2604-0) on June 29, 2026, and is solely responsible for the information contained therein.